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Abstract Background Nonsevere haemophilia A (HA) patients can be treated with desmo-
pressin. Response of factor VIII activity (FVIII:C) differs between patients and is difﬁcult
to predict.
Objectives Our aims were to describe FVIII:C response after desmopressin and its
reproducibility by population pharmacokinetic (PK) modelling.
Patients and Methods Retrospective data of 128 nonsevere HA patients (age
7–75 years) receiving an intravenous or intranasal dose of desmopressin were used.
PK modelling of FVIII:C was performed by nonlinear mixed effect modelling. Reprodu-
cibility of FVIII:C response was deﬁned as less than 25% difference in peak FVIII:C
between administrations.
Results A total of 623 FVIII:C measurements from 142 desmopressin administrations
were available; 14 patients had received two administrations at different occasions.
The FVIII:C time proﬁle was best described by a two-compartment model with ﬁrst-
order absorption and elimination. Interindividual variability of the estimated baseline
FVIII:C, central volume of distribution and clearance were 37, 43 and 50%, respectively.
The most recently measured FVIII:C (FVIII-recent) was signiﬁcantly associated with
FVIII:C response to desmopressin (p < 0.001). Desmopressin administration resulted
in an absolute FVIII:C increase of 0.47 IU/mL (median, interquartile range: 0.32–0.65
IU/mL, n ¼ 142). FVIII:C response was reproducible in 6 out of 14 patients receiving
two desmopressin administrations.
Conclusion FVIII:C response to desmopressin in nonsevere HA patients was ade-
quately described by a population PK model. Large variability in FVIII:C response was
observed, which could only partially be explained by FVIII-recent. FVIII:C response was
not reproducible in a small subset of patients. Therefore, monitoring FVIII:C around
surgeries or bleeding might be considered. Research is needed to study this further.
received
June 6, 2017
accepted after revision
December 1, 2017
Copyright © 2018 Schattauer DOI https://doi.org/
10.1160/TH17-06-0390.
ISSN 0340-6245.
Coagulation and Fibrinolysis 621
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
Introduction
Haemophilia A (HA) is a hereditary bleeding disorder, char-
acterized by a deﬁciency of coagulation factor VIII (FVIII).
Nonsevere HA patients (FVIII 0.01–0.40 IU/mL) suffer from
a bleeding risk after minor trauma and during surgical
interventions. To prevent or treat bleeding, FVIII concentrate
or desmopressin can be administered. Desmopressin is a
synthetic analogue of vasopressin and improves haemostasis
by release of endogenous FVIII and von Willebrand factor
(VWF) from storage sites in the endothelium.1,2 Desmopres-
sin is inexpensive, widely available and only sporadically
causes adverse reactions.3
In general, a desmopressin test dose is administered to
nonsevere HA patients to evaluate individual FVIII:C
response. This is important as the absolute increase of
FVIII:C following desmopressin administration varies
between patients. Moreover, not every patient reaches ade-
quate FVIII:C levels to prevent or treat bleeding. Several
factors have been identiﬁed that seem to inﬂuence the
FVIII:C response. The lowest FVIII:C level ever measured
(FVIII-lowest) has a positive correlation with the absolute
increase in FVIII:C after desmopressin.4–6 In addition, multi-
ple F8-gene mutations have been reported to affect
response.7,8 However, reliable prediction of individual
FVIII:C response remains difﬁcult. In addition, reproducibil-
ity is an issue. Reproducibility was previously deﬁned as
follows: a maximum deviation of 20% of a single FVIII:C
response from the average FVIII:C response in one patient.
Rodeghiero et al found this to be the case in 70% of patients.
However, these observations were made in only 10 adult HA
patients.9
Population pharmacokinetics (PK) may be a valuable new
approach to quantify and predict the FVIII:C response to
desmopressin. Previous studies have shown the merit of
developing population PK models for individualizing prophy-
lactic and perioperative dosing of FVIII concentrate treatment
in severe and moderate–severe HA patients.10–12 A large
advantage of population PK modelling is that only a limited
number of samples per patient is required as all patient data
are analysed simultaneously. In addition, patients with a
variable number of samples available can be included in the
analysis. With population PK modelling, the interindividual
variability (IIV) in FVIII:C response can be quantiﬁed. In
addition, it may lead to the identiﬁcation of covariates which
explain this IIV in the observed response, enabling prediction
of desmopressin response in individual patients.
Our aim was to assess the population PK of FVIII:C
following administration of desmopressin, to quantify the
IIV in FVIII:C response and to identify covariates explaining
this IIV. In addition, reproducibility of FVIII:C response was
assessed.
Patients and Methods
This study was a retrospective cohort study and was not
subjected to theMedical Research Involving Human Subjects
Act (WMO).
Patient Inclusion
All nonsevere HA patients (FVIII0.01 IU/mL) in the Erasmus
University Medical Centre, Rotterdam were screened.
Patients were included if they had received at least one
administration of desmopressin with at least one FVIII:C
measurement around the desmopressin administration.
Patients were only included if they had had at least 3 days
without desmopressin or FVIII concentrate treatment prior
to desmopressin administration.
Desmopressin Administration
Patients either received a standard dose of 0.3 μg/kg desmo-
pressin intravenously without a maximum or capped dose,
which was administered in 30 minutes or an intranasal dose
of desmopressin in a standard dose of 300 μg. FVIII:C was
measured bya one-stage assay. In case of a desmopressin test
dose, FVIII:C was measured prior to desmopressin adminis-
tration and at multiple time points after administration. The
time points for blood sampling were 0.5, 1, 2, 3, 4, 6 and
24 hours after desmopressin administration. The number of
obtained samples differed per patient depending on the
protocol, with a maximum of seven samples after desmo-
pressin administration. In patients receiving desmopressin
as treatment for bleeding or as prophylaxis before surgical
interventions, FVIII:C was measured before and between 0.5
and 2 hours after administration.
Data Collection
All data were extracted from patient ﬁles. Demographic data
including height and body weight were documented. The
following FVIII:C measurements were collected: FVIII-low-
est, the lowest FVIII:C ever measured in a patient (before or
after desmopressin administration), and the most recently
measured FVIII:C (FVIII-recent). FVIII-recent was deﬁned as
the most recent FVIII:C measurement, obtained  1 day
before the desmopressin administration and in the absence
of a treatment effect on FVIII values before the desmopressin
administration (►Fig. 1a). In addition, the reason for desmo-
pressin administration was documented (test, treatment or
prophylaxis). When available, the following data were col-
lected: VWF antigen (VWF:Ag), both historical and after
desmopressin administration, blood type, F8-genemutation,
platelet count and activated partial thromboplastin time
(aPTT).
Population Pharmacokinetic Modelling
A compartmental population PK model was developed
describing the time proﬁle of FVIII:C after desmopressin
administration, including its IIV and intraindividual varia-
bility using the software package NONMEM (7.1.2; Icon
Development Solutions, Ellicott City, Maryland, United
States). Since no actual FVIII concentrate was administered,
the dose was arbitrarily set to unity. Consequently, the
estimated PK parameters represent apparent PK parameters.
The ﬁrst step in model development was to test how many
compartments best ﬁtted the data. For this purpose, all data
were simultaneously ﬁtted, ﬁrst to a one-compartment
model and subsequently to a two-compartment model and
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the goodness-of-ﬁt between both was compared, as
described later. Estimated parameters were a ﬁrst-order
absorption rate constant (ka), clearance (CL) and central
volume of distribution (V1). In case of a two-compartment
model, peripheral volume of distribution (V2) and intercom-
partmental clearance (Q) were also estimated. As nonsevere
HApatientswere included, patients had ameasurable FVIII:C
before administration of desmopressin. Therefore, estima-
tion of baseline FVIII:C was performed in the population
analysis (►Fig. 1a). In the model, FVIII:C increase following
desmopressin administration was added to the estimated
baseline FVIII:C. More details on the modellingmethodology
are provided in ►Supplementary Table 1.
Whether IIV and intraindividual variability could be
explained by patient and/or haemophilia characteristics
were tested in a covariate analysis (see ►Supplementary
Table 1, Eqs. 4 and 5 for further details). Correlations were
ﬁrst tested in a univariate analysis for the following covari-
ates: FVIII-lowest, FVIII-recent, F8-gene mutation domain,
historical VWF:Ag, VWF:Ag during desmopressin adminis-
tration, aPTT, platelet count, blood type, body weight, age,
route of administration and indication for desmopressin
administration (test, bleeding, prophylaxis before surgery).
Subsequently, amultivariate analysis was performedwith all
statistically signiﬁcant covariates from the univariate analy-
sis with forward addition and backward elimination to
obtain the ﬁnal population model.
Improvement of the population model by adding a com-
partment or by implementing an association between a
covariate and a PK parameter was evaluated on the basis of
the likelihood ratio test. A p-value <0.001 was considered
statistically signiﬁcant, except for the univariate covariate
analysis, where p <0.05 was considered statistically signiﬁ-
cant. Furthermore, goodness-of-ﬁt was judged by visual
inspection of diagnostic plots as is the golden standard in
population PK analysis.13 These diagnostic plots were cre-
ated using Pirana (version 2.9.0) and Xpose (version 4.3.2,
Nicolas Jonsson andMats Karlsson, Uppsala, Sweden).13–15 A
visual predictive check (VPC) was done to investigate
whether the model adequately describes the observed
time course of FVIII:C response and the variability within
it. VPC analyses were performed using Perl speaks NONMEM
(PsN, version 3.5.3, Uppsala, Sweden).16
FVIII:C Response
The FVIII:C response to desmopressin was deﬁned as absolute
increase of FVIII:C (expressed as IU/mL) from the estimated
baselineFVIII:C, that is, thedifferencebetweenpeakFVIII:Cafter
desmopressin andbaseline FVIII:C. To calculate the peak FVIII:C,
individual estimates of the PK parameters (baseline FVIII:C, CL
and V1) were obtained by Bayesian analysis using the ﬁnal
population PK model. Subsequently, these individually esti-
mated PK parameters were used to construct the individual
FVIII:C response–timecurvebycalculating the individualFVIII:C
response every 10 minutes from the moment of desmopressin
administration until 24 hours thereafter. The highest estimated
FVIII:C response was taken as the peak FVIII:C (►Fig. 1b).
Duration of response was calculated in patients with peak
FVIII:C above certain target FVIII:C levels. These target levels
were chosen according to the guidelines for surgeries and other
procedures.17Partial responsewasdeﬁnedas the timeperiodof
FVIII:C above 0.30 IU/mL and complete responsewas deﬁned as
the timeperiod above 0.50 IU/mL (►Fig. 1a). Themoment from
reaching the target levelsuntil the individuallyestimatedFVIII:C
response dropped below these target levels was taken as the
duration of response. Reproducibility was deﬁned as a differ-
ence in estimated peak FVIII:C of less than 25% between
separate desmopressin administrations. This cutoff value is
common in bioequivalence studies.18
Results
In total, 128 nonsevere HA patients were included. Median
age was 28 years (range: 7–75) with 34 (24%) <18 years at
the time of desmopressin administration (N ¼ 142). Median
FVIII-lowest was 0.10 IU/mL (interquartile range [IQR]: 0.04–
0.18 IU/mL). Twenty-one patients had moderate HA (16%)
Fig. 1 (a) Deﬁnitions of FVIII parameters depicted in a curve of FVIII:
C response to desmopressin. FVIII, factor VIII; FVIII:C, response of
factor VIII activity; FVIII-lowest, lowest FVIII:C ever measured; FVIII-
recent, most recently measured FVIII:C 1 day before desmopressin
administration without previous treatment; baseline FVIII, estimated
FVIII:C directly before desmopressin administration; FVIII response,
estimated peak FVIII:C minus estimated baseline FVIII; duration of
response, time FVIII:C is above 0.5 or 0.3 IU/mL (in hours). (b)
Example of an individual response–time curve. Highest point in the
curve is the estimated peak FVIII:C (arrow). The individual pharma-
cokinetic estimates of this patient: estimated baseline FVIII:C ¼ 0.19
(IU/mL); volume of distribution ¼ 1.49 (L); clearance ¼ 0.27 (L/h).
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and 107 mild HA (84%). In 126 administrations (92%),
desmopressin was given intravenously and in 11 adminis-
trations (8%) intranasally. In 14 patients, repeated desmo-
pressin administrationswere performedwith available FVIII:
C measurements. The speciﬁc reasons for repeated monitor-
ing were unknown in 7 out of 14 patients. In three patients,
only limited FVIII:C measurements were available after the
ﬁrst desmopressin administration. In these patients, a more
extensive test was performed at a later time point to evaluate
long-term response. In four patients, one of the administra-
tions was performed intranasal and the other one intrave-
nously, and therefore, response was re-evaluated. In total,
142 desmopressin administrations were included, 83%
(n ¼ 109) of which was a test administration, 7% (n ¼ 9)
prophylactic and 10% (n ¼ 13) treatment for
bleeding. ►Table 1 shows all demographic data. Together
all desmopressin administrations resulted in 623 FVIII:C
measurements (►Fig. 2). ►Supplementary Tables 1 and 2
summarize the number of FVIII:C measurements collected
per sample time and per patient.
Population Pharmacokinetic Modelling
The two-compartment model was superior to the one-com-
partment model in describing FVIII:C increase and was
therefore used as the basic model. The model comprised a
ﬁrst-order rate constant (ka) describing the rate of the
increase of FVIII:C following desmopressin administration
and the apparent PK parameters V1, CL, V2 and Q (►Fig. 3).
IIV could be estimated for baseline FVIII:C, V1 and CL; the
respective values were 81, 67% and 86%. Intraindividual
variability could be estimated for baseline FVIII:C and for
V1, 29 and 38%, respectively (►Table 2).
Covariate Analysis
For all tested covariates at least 73% of data were available
(►Tables 1 and 3). However, for VWF:Ag during desmopres-
sin administration, platelet count and aPTT less than 60% of
data were available and these variables were therefore
excluded from the covariate analysis. The multivariate ana-
lysis showed FVIII-recent (85% of data available) to be
strongly positively correlated with estimated baseline
FVIII:C (p < 0.001) and negatively correlated with V1 and
CL (p < 0.001 for both) (see ►Table 3 for the univariate
analysis). The identiﬁed correlations are reﬂected by three
equations (►Table 2), which are derived from Eqs. 4 and 5 in
►Supplementary Table 1 (where these equations are further
explained).
►Fig. 4 illustrates the effect of these covariates on the
FVIII:C response–time curve according to the ﬁnal model for
ﬁve typical patients with all median characteristics of the
population, except for their FVIII-recent. For FVIII-recent, the
5th, 25th, 75th and 95th percentiles and the median were
chosen. A higher FVIII-recent correlates with a higher base-
line FVIII and with a higher absolute increase of FVIII:C after
Table 1 Demographic data
Patient characteristics
Age (y) (range) (n ¼ 142) 28 (7–75)
Weight (kg) (range) (n ¼ 111) 75 (26–120)
Mutation domain (n ¼ 110)
A1 24 (22%)
A2 37 (34%)
A3 5 (5%)
B 7 (6%)
C1 26 (24%)
C2 11 (10%)
Moderate HA (n ¼ 128) 21 (16%)
Blood type O (n ¼ 113) 48 (42%)
FVIII-lowest (IU/mL) (IQR) (n ¼ 128)a 0.10 (0.04–0.18)
FVIII-recent (IU/mL) (IQR) (n ¼ 120)a 0.15 (0.08–0.24)
Historical VWF:Ag (IU/mL) (IQR)
(n ¼ 104)
1.13 (0.91–1.55)
Intranasal administration (N ¼ 137) 11 (8%)
Indication for desmopressin
administration (n ¼ 131)b
Test dose 109 (83%)
Prophylaxis 9 (7%)
Treatment for bleed 13 (10%)
Abbreviations: IQR, interquartile range; HA, haemophilia A; FVIII-lowest,
lowest ever measured FVIII value; FVIII-recent, most recently FVIII value,
1 day before desmopressin administration; VWF:Ag, von Willebrand
factor antigen.
Note: Data were expressed as median with (IQR) or as frequency (%).
aIn 15 patients, FVIII-lowest was equal to FVIII-recent.
bAll desmopressin administrations. Fourteen patients had two admin-
istrations included in this study, total is 142.
Fig. 2 VPC: the 5th, 50th and 95th percentiles of FVIII:C responses as
measured (solid [50th percentile] and dotted [5th and 95th percen-
tile] lines) are within the 95% conﬁdence interval of the 5th, 50th and
95th percentiles of FVIII:C response that are predicted by the ﬁnal
model (shaded areas), indicating absence of bias. The VPC also shows
that the model does not underpredict or overpredict the variability of
FVIII:C response, since 5% of measured FVIII:C responses (open
circles) is less than the 95% conﬁdence interval of the predicted 5th
percentile or more than the 95% conﬁdence interval of the predicted
95th percentile of FVIII:C responses. FVIII, factor VIII; FVIII:C, response
of factor VIII activity; VPC, visual predictive check.
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desmopressin administration. It also correlates with a longer
duration of the FVIII:C response above 0.50 and 0.30 IU/mL.
Upon implementation of the signiﬁcant covariates in the
ﬁnal population model, IIV in baseline FVIII:C decreased
from 81 to 37%. IIV of V1 and CL decreased from 67 to 43%
and 86 to 50%, respectively. The model ﬁts the data ade-
quately, which is shown in the VPC (►Fig. 2). The data as
measured (dotted and solid lines) fall within the predicted
values (shaded areas), indicating absence of bias. Good-of-ﬁt
is also shown in ►Supplementary Fig. 1–c.
FVIII:C Response to Desmopressin
By using the ﬁnal and validatedmodel, the deﬁnedmeasures
of FVIII:C response to desmopressin were calculated. The
median absolute increase in FVIII:C was 0.47 IU/mL (IQR:
0.32–0.65 IU/mL, n ¼ 142). Half-life of FVIII:C had a median
of 5.8 hours with an IQR of 4.2 to 7.9 hours. In 128 (90%)
desmopressin administrations, peak FVIII:C was>0.30 IU/mL.
Median duration of FVIII:C>0.30 IU/mL was 9.8 hours (IQR of
4.3–22.6 hours). A peak FVIII:C >0.50 IU/mL was reached in
63% of patients. The FVIII:C remained above 0.50 IU/mL
in these patients for a median time of 4.8 hours (IQR of
2.1–10.7 hours). FVIII:C > 0.50 IU/mL for more than 24 hours
was seen in 11 patients (7.7%); FVIII:C >0.30 IU/mL in 29
patients (20%).
In the 14 patients with repeated desmopressin adminis-
trations, the median time between administrations was
30 months (IQR: 17–129 months). In 6 out of 14 (43%), a
reproducible response was observed. In three (21%) patients,
a higher second peak FVIII:C was seen, whereas ﬁve (36%)
other patients had a lower peak FVIII:C. The maximum
difference was 58% between administrations. All individual
responses are shown in ►Fig. 5.
Discussion
We have assessed the population PK of FVIII:C following
desmopressin administration in 128 nonsevere HA patients.
Our model shows a high IIV in FVIII:C response. In addition,
our results suggest that the FVIII:C response to desmopressin
is not reproducible in all patients. Only 6 out of 14 of patients
with repeated desmopressin administrations had similar
peak FVIII:C values after both administrations.
The high IIV could partially be explained by FVIII-recent.
FVIII-recent had a positive correlation with baseline FVIII:C
and a negative correlation with V1 and clearance. Previous
studies found FVIII-lowest and not FVIII-recent to be pre-
dictive of the FVIII:C response, although FVIII-recent was
never deﬁned as a separate covariate.4,6,19 Both FVIII-recent
and FVIII-lowest were not inﬂuenced by previous treatment
with FVIII concentrate or desmopressin and are the result of
endogenous synthesis. Therefore, both parameters could be
related to the response to desmopressin. Why FVIII-recent
was found rather than FVIII-lowest may be explained by the
fact that FVIII:C increases over time in patients with non-
severeHA (0.0064 IU/mLper decade) and is therefore a better
marker for current endogenous capacity.5,8,20–27 FVIII-recent
could not explain the IIVentirely. This might mean that other
covariates are of interest. One candidatemay be the exposure
to desmopressin as that would enable a better description
and prediction of the FVIII:C response in theory. Unfortu-
nately, desmopressin plasma levels were not available. Two
previous studies investigated the relationship between des-
mopressin plasma levels and the FVIII:C response in healthy
volunteers (N ¼ 10) and HA patients (N ¼ 14) and found no
correlation.28,29 Both studies hypothesized their ﬁndings
could be due to a ceiling effect of desmopressin. Further
research is needed to investigate this.
Interestingly, we did not ﬁnd signiﬁcant associations for
two other covariates which previously have been described
to correlate with the FVIII:C response. First, we studied age
extensively as a covariate, but it was not signiﬁcantly corre-
latedwith anyof the PK parameters. Contrary to our ﬁndings,
Di Perna et al found more responders in groups with an
increasingly higher age after dividing their patient popula-
tion in age groups of 10 years (N ¼ 75).4 Nolan et al reported
similar ﬁndings.30 Castaman et al only found age to be a
signiﬁcant covariate in a subgroup of patients with a speciﬁc
mutation.5 The different ﬁndings may be explained by the
fact that none of these studies used PK modelling to test
covariates. In addition, FVIII-recent was included as a cov-
ariate in our study and FVIII:C levels are correlated with
age.20 Therefore, it might be possible that a correlation
between FVIII response and age of previous studies is
explained by a change in FVIII levels over time.
Second, VWF was not a covariate in our model. VWF
protects FVIII from clearance and is also released from the
endothelium in response to desmopressin.1,25 Therefore, we
expected VWF to have an inﬂuence on FVIII:C response.
However, Castaman et al studied the inﬂuence of VWF on
FVIII:C response in HA patients and actually found a negative
correlation between VWF:Ag and peak FVIII:C level in
Fig. 3 Two-compartment model for FVIII after desmopressin
administration. FVIII, factor VIII; Ka, ﬁrst-order rate constant
describing the rate of the FVIII level increase after desmopressin
administration; estimated baseline FVIII, estimated FVIII:C directly
before desmopressin administration; Q, intercompartmental
clearance.
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patients with an identiﬁed F8-gene mutation.5 The reasons
we did not ﬁnd a correlation may be the missing VWF data
after desmopressin administrations and the lack of repre-
sentativeness of historical VWF values.
Median half-life of FVIII after desmopressin administra-
tion in this cohort (median 5.8 hours) was shorter than half-
life from FVIII concentrates reported in literature (8–
12 hours). In a previous study, half-life of FVIII:C after
desmopressin infusion ranged from 1.3 to 11.8 hours in a
subset of HA patients.5 Ludlam et al found a FVIII half-life
after desmopressin of approximately 4.5 hours in healthy
subjects and 3 hours in HA patients.31 Difference in half-life
between FVIII concentrate and endogenous FVIII after des-
mopressin may be due to the mutation in endogenous FVIII,
especially as half-life after desmopressin seems lower in
patients than in healthy subjects. However, Mannucci et al
showed the opposite as they found a half-life of 4.4 hours in
healthy subjects and 11.2 hours in HA patients.32 This
suggests that other mechanisms may play a role, but more
research is needed is to investigate this.
Another difference with previous research is that we
found a reproducibility in response of 43%, which was 15%
lower than reported previously. Rodeghiero et al found a
reproducibility of 70% among10HApatients.9However, they
deﬁned reproducibility as a deviation of peak FVIII:C on one
occasion relative to the average peak FVIII:C in that patient,
with a margin of 20%. In contrast, we used a difference
between peak FVIII:C of maximally 25%, as this value is
Table 2 Parameter estimates of the ﬁnal FVIII population pharmacokinetic model (with covariates) and the model without
covariates
Parameter Model without covariates Final model with covariates
Estimate RSE (%) Estimate RSE (%)
Baseline FVIII parameter (IU/mL) 0.14 6.9 0.15 4.6
ka (h-1) 3.8 16 3.8 24
V1 (L) 1.8 6.4 1.7 6.9
CL (L/h) 0.26 7.8 0.26 6.5
V2 (L) 0.23 23 0.24 36
Q (L/h) 0.13 21 0.11 48
Interindividual variabilitya
Baseline FVIII parameter (%) 81 16 37 99
V1 (%) 67 27 43 33
CL (%) 86 17 50 22
Correlation IIV baseline FVIII parameter and IIV V1 0.89 18 0.87 34
Intraindividual variabilitya
Baseline FVIII parameter (%) 29 47 38 71
V1 (%) 38 39 38 28
Residual variability
Proportional error (%) 12 9.7 12 9.7
Additive error (IU/mL) 0.018 19 0.018 20
Covariate correlations
FVIIIrecent–baseline FVIII parameter – – 0.74 18
Correction factor when FVIIIrecent is not available – – 1.2 15
FVIIIrecent–V1 – – 0.61 16
Correction factor when FVIIIrecent is not available – – 1.1 15
FVIIIrecent–CL – – 0.73 10
Correction factor when FVIIIrecent is not available – – 0.78 17
Abbreviations: CL, apparent FVIII clearance; IIV, interindividual variability; FVIII, factor VIII; IIV, interindividual variability; IOV, interoccasion
variability; ka, ﬁrst-order rate constant describing the rate of the FVIII level increase after desmopressin administration; Q, apparent inter-
compartmental clearance; RSE, relative standard error; V1, apparent central volume of distribution; V2, apparent peripheral volume of distribution.
Note: Equations for the identiﬁed correlations are as follows:
Estimated baseline FVIIIij ¼ 0.15  (FVIII-recent/0.15)(0.74  missing FVIIIrecentij)  1.2(1missing FVIII-recentij) (Eq. 1)
FVIII CLij ¼ 0.26  (FVIII-recent/0.15)(0.73  missing FVIIIrecentij)  0.77(1missing FVIIIrecentij) (Eq. 2)
FVIII V1ij ¼ 1.7  (FVIII-recent/0.15)(0.61  missing FVIIIrecentij)  1.1(1missing FVIIIrecentij) (Eq. 3).
aIIV and intraindividual variability estimates are expressed as coefﬁcients of variation.
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used in the European bioequivalence guideline.18 If this
deﬁnition is applied to the data of Rodeghiero et al, 60% of
patients would have had a reproducible FVIII:C response. In
addition, themedian timebetween desmopressinwas higher
in our population (30months) than in the previous study (14
months).9 This may indicate that response to desmopressin
changes over a longer period of time.
Our ﬁndings may have treatment implications. Currently,
FVIII:C response is often not monitored in patients with an
adequate previous response to desmopressin. This might be
reconsidered as FVIII-recent seems more predictive for
response than FVIII-lowest and as 5 out of 14 patients had
a signiﬁcantly lower response after a second desmopressin
administration at a different occasion.
Regarding the observed reproducibility in our cohort, it
seems that patients with a low response were more likely to
be re-evaluated, as FVIII-recent and FVIII:C response were
lower in patients with two desmopressin administrations
than in patients with one desmopressin administration (data
not shown). Given this aspect and the fact that reproduci-
bility could only be assessed in 14 patients, our ﬁndings may
not represent the reproducibility of testing in the entire
cohort. Unfortunately,wewere not able to identify covariates
that may predict which patients are at risk of a
nonreproducible second response, most likely as a result of
lack of statistical power due to the small sample size.
Nevertheless, the results on reproducibility might suggest
that measuring a trough and peak FVIII:C level around
(surgical) interventions may be considered in some patients,
also when results of earlier FVIII:C response after desmo-
pressin administration are available, depending on the con-
sequences of bleeding during or after a speciﬁc intervention.
More speciﬁc recommendations can only be made when our
results are conﬁrmed in a larger dataset, as also the only
other study looking into reproducibility included a low
number of patients.9,10
A few other limitations were present in this study. First,
data collectionwas performed retrospectively. Therefore, not
all parameters were available in each patient, leading to
missing data. This may have limited the power for the
identiﬁcation of associations between PK parameters and
covariates, for example, VWF. Second, F8-gene mutations
Table 3 Tested covariates in univariate analysis
Covariate Outcome univariate analysis
Baseline FVIII CL V1
Mutation domain
A1 NS NS NS
A2 NS NS NS
A3 NS p < 0.05 NS
B NS NS NS
C1 p < 0.001 p < 0.01 NS
C2 NS NS NS
FVIII-recent p < 0.001 p < 0.001 p < 0.01
Abbreviations: CL, apparent FVIII clearance; FVIII-recent, recently mea-
sured FVIII:C; NS, nonsigniﬁcant; V1, apparent central volume of
distribution.
Note: Age, weight, administration mode, blood type, FVIII-lowest, most
recently measured von Willebrand factor antigen, desmopressin dose
and indication for desmopressin (test, bleeding and prophylaxis before
surgery) were no signiﬁcant covariates. aPTT, platelet count and von
Willebrand factor antigen during desmopressin administration were not
tested as covariates due to too many (>40%) missing data.
Fig. 5 Reproducibility of FVIII:C to desmopressin. Individual
response showing baseline FVIII:C (left bar) and peak FVIII:C (right bar)
for both the ﬁrst (black) and second (grey) desmopressin adminis-
tration. FVIII:C, response of factor VIII activity.
Fig. 4 FVIII:C response–time curves according to the ﬁnal model.
Response–time curves for ﬁve typical patients with all median char-
acteristics of the population, but with a FVIII-recent of 0.04 (5th
percentile), 0.08 (25th percentile), 0.15(median), 0.24 IU/mL (75th
percentile) or 0.47 (95th percentile). DDAVP, desmopressin; FVIII,
factor VIII; FVIII:C, response of factor VIII activity.
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were divided into six groups according to their domains: A1,
A2, B, A3, C1 and C2. We did not study individual mutations
as the subgroups would become too small. Therefore, the
inﬂuence of some mutations may have been missed, as
different mutations in the same domain may have opposite
effects. Third, our model is an empirical model describing
only the data. A mechanistic model might give more insight
into the physiology of FVIII after desmopressin administra-
tion. A ﬁnal limitation could have been that all data were
analysed without dividing the population into groups
according to the indication for desmopressin administration
(test, bleeding and prophylaxis). However, as treatment
indication was not a signiﬁcant covariate, separate analysis
would not yield different results, while statistical power
would be diminished.
Overall, an adequate population PK model was con-
structed that describes desmopressin response in nonsevere
HA patients. Much IIV remains unexplained, despite identi-
ﬁcation of the most recently FVIII:C as signiﬁcant covariate.
In addition, reproducibility of response may be lower than
previously thought. Therefore, a desmopressin test dose in
each patient remains necessary. In addition, monitoring of
FVIII:C response to desmopressin around (surgical) inter-
ventions or in case of bleeding may be considered in some
patients. More research is needed to investigate the repro-
ducibility of response to desmopressin.
What is known about this topic?
• The FVIII:C response to desmopressin varies between
HA patients.
• The FVIII:C response to desmopressin remains difﬁcult
to predict.
What does this paper add?
• PK modelling is useful to describe the FVIII:C response
to desmopressin in haemophilia A.
• The most recent FVIII:C level inﬂuences the FVIII:C
response.
• The FVIII:C response may not be reproducible in some
HA patients.
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